{
    "nct_id": "NCT03988595",
    "official_title": "Phase 1 Trial of Exercise Treatment With Concurrent First-Line Therapy for Hormone Receptor Positive Metastatic Breast Cancer",
    "inclusion_criteria": "* Patients with histologically-confirmed, HR-positive (ER and/or PR), HER2-negative metastatic breast cancer (MBC)\n* Postmenopausal status defined by lack of menses for 2 years, oophorectomy, or medical ovarian suppression\n* Receiving first line endocrine-based therapy (tamoxifen, aromatase inhibitor, or fulvestrant; concurrent molecular therapy also allowed)\n* Sedentary (i.e., <60 minutes / week of exercise)\n* Age >18 years\n* BMI ≥ 18.5\n* Cleared for exercise participation as per screening clearance via PAR-Q+\n* Cleared for study participation as per screening consultation with an MSK Exercise Physiologist\n* Willingness to comply with all study-related procedures\n* Patients with \"treated and stable\" brain lesions of a duration of ≥ 2 months may be enrolled\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 19 Years",
    "exclusion_criteria": "* Life expectancy <6 months\n* Enrollment onto any other therapeutic investigational study\n* Mental impairment leading to inability to cooperate\n* Concurrent participation in weight loss or other exercise programs",
    "miscellaneous_criteria": ""
}